{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:19:00Z","timestamp":1761765540493},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.ejca.2012.01.025","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T22:15:35Z","timestamp":1329430535000},"page":"1657-1663","source":"Crossref","is-referenced-by-count":10,"title":["Does baseline total testosterone improve the yielding of prostate cancer screening?"],"prefix":"10.1016","volume":"48","author":[{"given":"Francisco","family":"Botelho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Pina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"Lunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2012.01.025_b0005","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2012.01.025_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1098-2388(200001\/02)18:1<3::AID-SSU2>3.0.CO;2-I","article-title":"Prostate-specific antigen","volume":"18","author":"Brawer","year":"2000","journal-title":"Semin Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2012.01.025_b0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2010.04.001","article-title":"Testosterone measurement in patients with prostate cancer","volume":"58","author":"Schulman","year":"2010","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.ejca.2012.01.025_b0020","first-page":"626","article-title":"The role of LHRH antagonists in the treatment of prostate cancer","volume":"23","author":"Crawford","year":"2009","journal-title":"Oncology (Williston Park)"},{"issue":"8","key":"10.1016\/j.ejca.2012.01.025_b0025","first-page":"3232","article-title":"Endogenous hormones as a major factor in human cancer","volume":"42","author":"Henderson","year":"1982","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2012.01.025_b0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/pros.2990100106","article-title":"Production, clearance, and metabolism of testosterone in men with prostatic cancer","volume":"10","author":"Meikle","year":"1987","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.ejca.2012.01.025_b0035","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000112602","article-title":"Testosterone levels in benign prostatic hypertrophy and prostate cancer","volume":"80","author":"Mearini","year":"2008","journal-title":"Urol Int"},{"issue":"3","key":"10.1016\/j.ejca.2012.01.025_b0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/1097-0045(20000801)44:3<219::AID-PROS6>3.0.CO;2-I","article-title":"Endocrine patterns in patients with benign and malignant prostatic diseases","volume":"44","author":"Schatzl","year":"2000","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.ejca.2012.01.025_b0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1745-7262.2008.00296.x","article-title":"Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men","volume":"10","author":"Hong","year":"2008","journal-title":"Asian J Androl"},{"issue":"5","key":"10.1016\/j.ejca.2012.01.025_b0050","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.juro.2008.01.045","article-title":"The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men","volume":"179","author":"Rhoden","year":"2008","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ejca.2012.01.025_b0055","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.urology.2006.08.1058","article-title":"Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0ng\/mL or less","volume":"68","author":"Morgentaler","year":"2006","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ejca.2012.01.025_b0060","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.urology.2005.04.012","article-title":"Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0ng\/mL","volume":"66","author":"Kravchick","year":"2005","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ejca.2012.01.025_b0065","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/bjc.1979.122","article-title":"Serum testosterone and dihydrotestosterone in carcinoma of the prostate","volume":"39","author":"Ghanadian","year":"1979","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2012.01.025_b0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/bjc.1993.293","article-title":"Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer \u2013 a population-based case\u2013control study","volume":"68","author":"Andersson","year":"1993","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2012.01.025_b0075","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1530\/acta.0.0850650","article-title":"Sex hormone binding globulin binding capacity, testosterone, 5alpha-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment","volume":"85","author":"Bartsch","year":"1977","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"9","key":"10.1016\/j.ejca.2012.01.025_b0080","first-page":"3864","article-title":"Effect of diet on plasma and urinary hormones in South African black men with prostatic cancer","volume":"42","author":"Hill","year":"1982","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2012.01.025_b0085","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/pros.10234","article-title":"Reduced circulating androgen bioactivity in patients with prostate cancer","volume":"55","author":"Raivio","year":"2003","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.ejca.2012.01.025_b0090","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1373\/clinchem.2005.048595","article-title":"Case\u2013control and two-gate designs in diagnostic accuracy studies","volume":"51","author":"Rutjes","year":"2005","journal-title":"Clin Chem"},{"issue":"22","key":"10.1016\/j.ejca.2012.01.025_b0095","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2012.01.025_b0100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/pros.1046","article-title":"High-grade prostate cancer is associated with low serum testosterone levels","volume":"47","author":"Schatzl","year":"2001","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.ejca.2012.01.025_b0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/pros.10140","article-title":"Association between prostate cancer and serum testosterone levels","volume":"53","author":"Zhang","year":"2002","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.ejca.2012.01.025_b0110","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1097\/01.ju.0000181818.51977.29","article-title":"Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer","volume":"174","author":"Teloken","year":"2005","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ejca.2012.01.025_b0115","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0022-5347(05)64623-X","article-title":"No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer","volume":"168","author":"Fodstad","year":"2002","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ejca.2012.01.025_b0120","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0022-5347(05)67812-3","article-title":"Is low serum free testosterone a marker for high grade prostate cancer?","volume":"163","author":"Hoffman","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ejca.2012.01.025_b0125","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/pcan.2008.35","article-title":"Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?","volume":"12","author":"Imamoto","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.ejca.2012.01.025_b0130","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.urology.2008.07.068","article-title":"Absence of relationship between steroid hormone levels and prostate cancer tumor grade","volume":"73","author":"Sher","year":"2009","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ejca.2012.01.025_b0135","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.eururo.2007.04.005","article-title":"Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship","volume":"52","author":"Morgentaler","year":"2007","journal-title":"Eur Urol"},{"issue":"6948","key":"10.1016\/j.ejca.2012.01.025_b0140","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/bmj.309.6948.188","article-title":"Diagnostic tests 3: receiver operating characteristic plots","volume":"309","author":"Altman","year":"1994","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejca.2012.01.025_b0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000102906","article-title":"Hormonal predictors of prostate cancer","volume":"79","author":"Sofikerim","year":"2007","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.ejca.2012.01.025_b0150","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-410X.2009.08378.x","article-title":"The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness","volume":"104","author":"Morote","year":"2009","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ejca.2012.01.025_b0155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.eururo.2006.08.047","article-title":"The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening","volume":"51","author":"Yano","year":"2007","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ejca.2012.01.025_b0160","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1464-410X.2009.08761.x","article-title":"Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk","volume":"105","author":"Morote","year":"2009","journal-title":"BJU Int"},{"issue":"8","key":"10.1016\/j.ejca.2012.01.025_b0165","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1373\/49.8.1381","article-title":"Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography\u2013mass spectrometry in sera from 116 men, women, and children","volume":"49","author":"Taieb","year":"2003","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.ejca.2012.01.025_b0170","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.urology.2008.03.033","article-title":"Prostate tissue androgens: history and current clinical relevance","volume":"72","author":"Marks","year":"2008","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ejca.2012.01.025_b0175","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0022-5347(01)62922-7","article-title":"Influence of radical prostatectomy on serum hormone levels","volume":"160","author":"Miller","year":"1998","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ejca.2012.01.025_b0180","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1677\/ERC-09-0070","article-title":"Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone","volume":"16","author":"Mizokami","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2012.01.025_b0185","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1439-0272.2009.00972.x","article-title":"Prostate cancer: a newly discovered route for testosterone to reach the prostate: treatment by super-selective intraprostatic androgen deprivation","volume":"41","author":"Gat","year":"2009","journal-title":"Andrologia"},{"issue":"1","key":"10.1016\/j.ejca.2012.01.025_b0190","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.eururo.2009.03.088","article-title":"Testosterone and prostate cancer: revisiting old paradigms","volume":"56","author":"Isbarn","year":"2009","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejca.2012.01.025_b0195","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth","volume":"55","author":"Morgentaler","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ejca.2012.01.025_b0200","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jnci\/djm323","article-title":"Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies","volume":"100","author":"Roddam","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ejca.2012.01.025_b0205","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.2009.08814.x","article-title":"Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?","volume":"105","author":"Perachino","year":"2010","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ejca.2012.01.025_b0210","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/01.ju.0000062674.43964.d0","article-title":"Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy","volume":"169","author":"Massengill","year":"2003","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ejca.2012.01.025_b0215","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13685530802400995","article-title":"Baldness, benign prostate hyperplasia, prostate cancer and androgen levels","volume":"11","author":"Faydaci","year":"2008","journal-title":"Aging Male"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912000664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912000664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T21:01:16Z","timestamp":1561323676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804912000664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0959804912000664"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.01.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}